<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358930</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 501-208</org_study_id>
    <nct_id>NCT00358930</nct_id>
  </id_info>
  <brief_title>A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule</source>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally
      advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the overall response rate (ORR) of patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with ARQ 501.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the progression-free survival (PFS) at six months for those patients treated with ARQ 501.To further characterize the safety ARQ 501.</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 501</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide signed and dated informed consent document prior to study-specific
             screening procedures.

          2. Histologically or cytologically confirmed locally advanced, recurrent or metastatic
             SCCHN.

          3. Measurable disease per RECIST.

          4. ≥ 18 years old.

          5. Karnofsky performance status (KPS) ≥ 70%.

          6. Male or female patients of child-producing potential must agree to use contraception
             or avoidance of pregnancy measures during the study and for 30 days after the last
             infusion of ARQ 501.

          7. Hemoglobin (Hgb) ≥ 10 g/dL.

          8. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (≥ 1,500/mm³).

          9. Platelet count ≥ 100 x 10^9/L ( ≥ 100,000/mm³).

         10. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) or less than
             or equal to 3.0 x ULN with metastatic liver disease.

         11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 2.5 x ULN or less than or equal to 5.0 x ULN with metastatic liver disease.

         12. Creatinine less than or equal to 1.5 x ULN.

        Exclusion Criteria:

          1. Primary tumor of nasopharyngeal origin.

          2. Eligible for curative surgery or radiotherapy.

          3. Received three or more systemic anticancer regimens.

          4. Have active, uncontrolled systemic infection considered opportunistic, life
             threatening or clinically significant at the time of treatment.

          5. Have received anticancer chemotherapy, immunotherapy, radiotherapy, or investigational
             agents within three weeks of first infusion.

          6. Surgery within two weeks of first infusion.

          7. Have symptomatic or untreated central nervous system (CNS) involvement.

          8. Are pregnant or lactating.

          9. Previous exposure to ARQ 501.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA County Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-0178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beta-lapachone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

